After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ACAD falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Acadia Pharmaceuticals Inc is $4.75B. A total of 1.61 million shares were traded on the day, compared to an average of 1.89M shares.
In the most recent transaction, Schneyer Mark C. sold 10,262 shares of ACAD for 23.69 per share on Nov 18 ’25. After the transaction, the EVP, CHIEF FINANCIAL OFFICER now owns 53,338 company shares. In a previous transaction on Nov 18 ’25, Kihara James sold 4,084 shares at 23.69 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 25,058.
Among the insiders who sold shares, Daly James M disposed of 30,000 shares on Nov 10 ’25 at a per-share price of $22.37. This resulted in the Director holding 4,041 shares of ACAD after the transaction. In another insider transaction, James M Daly bought 30,000 shares at $22.37 per share on Nov 10 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ACAD has a high of $27.73 and a low of $13.40.
As of this writing, ACAD has an earnings estimate of $0.14 per share for the current quarter. EPS was calculated based on a consensus of 16.0 estimates, with a high estimate of $0.23 per share and a lower estimate of -$0.03. The company reported an EPS of $0.86 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $5.42, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.05.
